Efficacy of Topical Ketorolac Versus Placebo for Improving Visual Outcomes Following Multifocal IOL Implantation

The purpose of this study was to evaluate the efficacy of ketorolac 0.4% on quality of vision and macula thickening in patients undergoing cataract surgery using the ReStor® multifocal IOL.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Macula Thickening

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Ophthalmic Consultants of Long Island

Rockville Centre, New York, 11570, United States

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Males or females > 50 years old
Scheduled to undergo bilateral phacoemulsification with implantation of a multifocal IOL.
Likely to complete all study visits and able to provide informed consent
Visual potential of 20/25 or better

Exclusion criteria

· Prior use of topical ketorolac

Known contraindications to any study medication or ingredients
Active ocular diseases or uncontrolled systemic disease
Active ocular allergies

Treatment and study plan

Prednisolone Acetate

Drug

Ketorolac 0.4%

Drug

Gatifloxacin 0.3%

Drug

Sponsors and collaborators

Lead sponsor

Innovative Medical

Industry

Registry information

Important dates

First posted: Feb 9, 2007
Registry last updated: Sep 10, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.